AGIO

Agios is a commercial-stage rare-disease biopharma whose economics are still pre-profit. FY2025 product revenue rose 48% to $54.0M on PYRUKYND, and the company just launched its second product, AQVESME (mitapivat in alpha/beta-thalassemia), in the US in late January 2026. The headline GAAP net income line is noise: the -$413M FY2025 loss followed a +$674M FY2024 'profit' and a +$1.60B FY2021 figure, both driven by one-time gains tied to the 2021 Servier oncology divestiture, not operations. The honest read is the operating loss of -$472M (operating margin -873.9%) and the -$373M operating cash burn — this is a company funding a heavy R&D program ($340M) against a tiny top line.

What keeps this out of 'avoid' is the balance sheet. Liabilities are just $104M against $1.19B of equity (0.09x liabilities/equity), and while cash & equivalents are only $89.1M, current assets total $942M — the bulk sitting in marketable securities. That funds roughly two-plus years of the current burn before a raise is forced, and shares grew only 2.3% YoY, so dilution has so far been modest. The pipeline carries real, dated catalysts: a positive CHMP opinion for thalassemia with a European Commission decision expected early 2026, a planned US sNDA submission for mitapivat in sickle cell disease after a Q1 2026 FDA meeting, and tebapivat, AG-181 (PKU) and the Alnylam-licensed AG-236 (PV) behind it. There is also a contingent $200M Servier payment if vorasidenib wins FDA approval before January 1, 2027.